News

On Friday 5 December, CSCI celebrated our fourth annual Christmas Market at the Jeffrey Cheah Biomedical Centre. Partnering with our neighbours at Cancer Research UK Cambridge Institute, Cambridge Biomedical Campus, The Milner Therapeutics Institute, and Cambridge Institute of Therapeutic Immunology & Infectious Disease, the building welcomed over …

Professor Sarah Teichmann (Chair in Stem Cell Medicine, Cambridge Stem Cell Institute, Department of Medicine, University of Cambridge) has been elected to the prestigious National Academy of Medicine in the USA. She was announced as one of 90 new regular members and 10 new international members during the annual meeting in Washington yesterday (20…

Stem Cell Reports, the official journal of the International Society for Stem Cell Research, has just welcomed Cambridge Stem Cell Institute Director Bertie Göttgens as one of 13 new distinguished researchers to the Editorial Board. The new appointments are designed to broaden representation across the international landscape of stem cell science a…

A groundbreaking study led by Professor George Vassiliou at the Cambridge Stem Cell Institute and University of Cambridge has revealed that age-related telomere shortening plays a key role in the development of clonal haematopoiesis (CH) and blood cancers driven by mutations in RNA splicing genes. The findings, published this week in Nature Genetic…

We are very excited to launch our new institute video, A Place of Possibility / Cambridge Stem Cell Institute, showcasing some of the people that form our research community. Watch this three-minute video to hear from our students, postdocs, facilities team, admin team, and Director as they demonstrate how the collaborative atmosphere of the Instit…

Last Thursday and Friday, the Institute held the CSCI Annual Retreat & Symposium on 26 and 27 June in Cambridge.This annual event brings together CSCI researchers, Affiliate Group Leaders, and our Stem Cells Interdisciplinary Research Centre members for a day and a half of talks, posters, Institute updates, and networking outside of the office and …

Yesterday the European Research Council (ERC) announced the winners of its latest Advanced Grant competition. CSCI’s Professor Walid Khaled was selected as one of 281 leading researchers across Europe to receive some of the 721 million euros in funding to pursue his breast cancer research. The ERC fund will provide €2.5 million over 5 years for the…

This past weekend, Professor Matthias Zilbauer of CSCI launched the new Cambridge Centre for Children’s Gut Health, welcoming over 100 children living with inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis. Zilbauer, Professor of Paediatric Gastroenterology at the University of Cambridge and a consultant at Addenbrook…

Research out this week finds that a combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), the most common cancer in childhood and one that can be particularly difficult to treat in older patients. In recent years, new treatments have begun to emerge, including bo…

Last week, the Cambridge Stem Cell Institute Technology & Innovation Forum (SCI-TIF) celebrated its 3rd Annual Networking Dinner at Homerton College, Cambridge. This event brought together leading scientists from academia and industry, reinforcing SCI-TIF’s mission to unite the Cambridge stem cell community and foster innovation through collaborati…

Professor Sarah TeichmannFMedSci FRS, Chair in Stem Cell Medicine at the University of Cambridge (Cambridge Stem Cell Institute & Dept Medicine), and Group Leader at CSCI, has been announced this week as one of the newest members of the prestigious American Academy of Arts & Sciences. Sarah says, “It is a tremendous pleasure and honour that our wor…

A new study from Dr Konstantinos Tzelepis at the Cambridge Stem Cell Institute has discovered a new way to detect and target Acute Myeloid Leukaemia (AML), a fast growing, aggressive, blood cancer that requires urgent treatment. The research was published today (23 April) in Nature Biotechnology. AML is the second most common leukaemia type, with 3…

Research out this week from the Vassiliou and Huntly Groups shows that a common diabetes drug could prevent a form of acute myeloid leukaemia in people at high risk of the disease. The research, published 16 April in Nature, found that metformin, a widely used and readily available diabetes drug, could prevent abnormal blood stem cells with genetic…

Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease. A new study has unveiled when chronic myeloid leukaemia, a type of cancer that affects the blood and bone marrow, arises in life and how fast it grows. Researchers reveal explosive growth rates of cancerous …

Last week (28March), the Zilbauer Group and the Cambridge Stem Cell Institute Technology and Innovation Forum (SCI-TIF) hosted the 1st Cambridge Human Organoid Symposium at Jesus College, Cambridge. The event brought together a diverse group of scientists, clinicians, and industry leaders to delve into the latest advancements in organoid technology…